{"schema_version":"1","generated_at":"2026-10-30T21:12:32.673Z","data_as_of":null,"url":"https://www.findmykol.com/kol/philomena-colucci","json_url":"https://www.findmykol.com/kol/philomena-colucci/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"philomena-colucci","name":"Philomena Colucci","credential":"DO","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Incyte","institution_url":"https://www.findmykol.com/institution/incyte","city":"Gaylord","state":"MI","region":{"label":"Midwest","url":"https://www.findmykol.com/region/midwest"}},"identifiers":{"npi":"1811012438","openalex":"A5075641618"},"summary":"Philomena Colucci is an Oncology physician affiliated with Incyte. OpenAlex indexes 53 publications with 405 citations (h-index 12); ClinicalTrials.gov lists 1 registered study matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":53,"cited_by_count":405,"h_index":12,"latest_activity_year":2025,"source":"works"},"trials":{"count":1,"shown":1,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT05949632","title":"A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors","phase":"PHASE1/PHASE2","status":"TERMINATED","role":"Overall official","sponsor":"Incyte Corporation","source_url":"https://clinicaltrials.gov/study/NCT05949632","trial_url":"https://www.findmykol.com/trial/NCT05949632"}],"source":"trials"},"payments":{"company_count":1,"program_years":{"first":2021,"last":null},"rows_total":1,"shown":1,"withheld":0,"rows":[{"payer":"ABBVIE INC.","program_year":2024,"amount_usd":24.6,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1811012438"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1811012438","source":"payments"},"publications":{"total":48,"shown":5,"withheld":43,"matched_by":"OpenAlex author record","recent":[{"title":"Pemigatinib for Myeloid/Lymphoid Neoplasms with <i>FGFR1</i> Rearrangement","year":2025,"journal":"NEJM Evidence","source_url":"https://doi.org/10.1056/evidoa2500017","status":"verified"},{"title":"Phase 3 study (inMIND) of tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: Clinical characteristics and outcomes of high-risk patients","year":2025,"journal":"Blood","source_url":"https://doi.org/10.1182/blood-2025-5367","status":"verified"},{"title":"Identification and Confirmation of Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 Rearrangement and Characterization of Treatment Patterns and Outcomes in a Real-World Setting: A US Retrospective Chart Review","year":2025,"journal":"Acta Haematologica","source_url":"https://doi.org/10.1159/000546910","status":"verified"},{"title":"POSTER: IBCL-625 Quality of Life (QoL) Outcomes With Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma (R/R FL): Results From a Phase 3, Double-Blind, Randomized, Placebo-Controlled, International, Multicenter Study (inMIND)","year":2025,"journal":"Clinical Lymphoma Myeloma & Leukemia","source_url":"https://doi.org/10.1016/s2152-2650(25)01121-8","status":"verified"},{"title":"IBCL-625: Quality of Life (QoL) Outcomes With Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma (R/R FL): Results From a Phase 3, Double-Blind, Randomized, Placebo-Controlled, International, Multicenter Study (inMIND)","year":2025,"journal":"Clinical Lymphoma Myeloma & Leukemia","source_url":"https://doi.org/10.1016/s2152-2650(25)02423-1","status":"verified"}],"source":"works"},"contact":{"address_1":"701 N OTSEGO AVE","city":"Gaylord","state":"MI","zip":"497351558","phone":"989-731-7760","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1811012438","source":"identity"},"similar":[{"name":"Gerard Kennealey","slug":"gerard-kennealey","institution":"Incyte","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/gerard-kennealey","json_url":"https://www.findmykol.com/kol/gerard-kennealey/profile.json"},{"name":"John Janik","slug":"john-janik","institution":"Incyte","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/john-janik","json_url":"https://www.findmykol.com/kol/john-janik/profile.json"},{"name":"Thomas Hultsch","slug":"thomas-hultsch","institution":"Incyte","url":"https://www.findmykol.com/kol/thomas-hultsch","json_url":"https://www.findmykol.com/kol/thomas-hultsch/profile.json"},{"name":"Evan Braunstein","slug":"evan-braunstein","institution":"Incyte","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/evan-braunstein","json_url":"https://www.findmykol.com/kol/evan-braunstein/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"publications":43}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2013-11-15","collected_at":"2026-10-27T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"}},"methodology_url":"https://www.findmykol.com/about#methodology"}